JNJ-1802 (Mosnodenvir) is an orally active pan-serotype dengue virus (DENV) inhibitor with EC50 values ranging from 0.057 to 11 nM against all four DENV serotypes; it blocks viral replication by inhibiting the formation of the complex between nonstructural proteins NS3 and NS4B, thereby preventing the synthesis of new viral RNA; it exhibits picomolar to nanomolar antiviral activity in vitro and demonstrates antiviral efficacy in mice and non-human primates.